SBIR Phase I: Genetically Engineered BCG as a Microbe-Based Platform for Vaccination Again — NSF Award to MANHATTAN BIOSOLUTIONS,
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop a safe and affordable COVID-19 vaccination technology, with broader utility in managing other contagious diseases. The new platform is based on modified bacteria, with a long history as a safe pediatr
| Award title | SBIR Phase I: Genetically Engineered BCG as a Microbe-Based Platform for Vaccination Again |
|---|---|
| Award ID | 2029504 |
| Awardee | MANHATTAN BIOSOLUTIONS, LLC |
| City | FORT LEE |
| State | NJ |
| Amount obligated | $256,000 |
| Principal investigator | Borys Shor |
| Program | SBIR Phase I |
| Start date | 09/01/2020 |
| Abstract | The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop a safe and affordable COVID-19 vaccination technology, with broader utility in managing other contagious diseases. The new platform is based on modified bacteria, with a long history as a safe pediatric immunization for tuberculosis. The proposed technology is expected to show heat-stability, safety, cost-effectiveness, and ease of mass production. It can be used for children a |
| Source | NSF Awards |
$799/mo
Try NSFGrants →